Drug Profile

Axitinib - Pfizer

Alternative Names: AG-013736; AG-13,736; Inlyta

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Developer Grupo Espanol de Tumores Neuroendocrinos; H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme; Netherlands Cancer Institute; Pfizer; Royal Marsden Hospital; SCRI Development Innovations; SFJ Pharmaceuticals; Sheffield Teaching Hospitals NHS Foundation Trust; University of Cincinnati; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
Class Antineoplastics; Benzamides; Eye disorder therapies; Imidazoles; Indazoles; Pyridines; Small molecules
Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Renal cell carcinoma
New Molecular Entity Yes

Marketed Renal cell carcinoma
Phase II/III Neuroendocrine tumours
Phase II Carcinoid tumour; Colorectal cancer; Endometrial cancer; Glioblastoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Soft tissue sarcoma; Urogenital cancer
No development reported Solid tumours
Discontinued Breast cancer; Gastric cancer; Gastrointestinal cancer; Pancreatic cancer; Thyroid cancer

28 Feb 2025 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO, Tablet)
13 Feb 2025 Efficacy and pharmacodynamics data from a phase II A-PREDICT trial in Renal cell carcinoma presented at the 2025 Genitourinary Cancers Symposium (ASCO-GeCS-2025)
26 Dec 2024 Expanded-access programme in Renal cell carcinoma is no longer available (NCT05941637)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com